WO2004019866B1 - Compositions and methods for treating cardiovascular disease - Google Patents

Compositions and methods for treating cardiovascular disease

Info

Publication number
WO2004019866B1
WO2004019866B1 PCT/US2003/026354 US0326354W WO2004019866B1 WO 2004019866 B1 WO2004019866 B1 WO 2004019866B1 US 0326354 W US0326354 W US 0326354W WO 2004019866 B1 WO2004019866 B1 WO 2004019866B1
Authority
WO
WIPO (PCT)
Prior art keywords
ibb
antagonist
antibody
group
ligand
Prior art date
Application number
PCT/US2003/026354
Other languages
French (fr)
Other versions
WO2004019866A2 (en
WO2004019866A3 (en
Inventor
Paul B Burton
Theresa A Deisher
Original Assignee
Immunex Corp
Paul B Burton
Theresa A Deisher
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunex Corp, Paul B Burton, Theresa A Deisher filed Critical Immunex Corp
Priority to MXPA05002219A priority Critical patent/MXPA05002219A/en
Priority to CA2496795A priority patent/CA2496795C/en
Priority to EP03791726A priority patent/EP1545578A4/en
Priority to JP2004532947A priority patent/JP2006508056A/en
Priority to AU2003259995A priority patent/AU2003259995B2/en
Publication of WO2004019866A2 publication Critical patent/WO2004019866A2/en
Publication of WO2004019866A3 publication Critical patent/WO2004019866A3/en
Publication of WO2004019866B1 publication Critical patent/WO2004019866B1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Transplantation (AREA)
  • Pulmonology (AREA)
  • Virology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention pertains to methods of treating cardiovascular disease by modulating inflammatory and immunoregulatory responses associated with such pathological conditions. Embodiments of the invention provide methods for the treatment of cardiovascular disease in a subject having cardiovascular disease comprising administering an effective amount of one or more IL-17 antagonists, IL-18 antagonists, 4-1BB antagonists, CD30 antagonists, OX40 antagonists and/or CD39 alone or in any combination. This abstract is provided for the sole purpose of enabling the reader to quickly ascertain the subject matter of the technical disclosure and is not intended to be used to interpret or limit the scope or meaning of the claims. 37 CFR 1.72(b).

Claims

AMENDED CLAIMS[received by the International Bureau on 13 May 2004 (13.05.04) new claimsl2-19 addedWhat is claimed is:
1. A method of reducing the effective amount of biologically active endogenous 4- IBB or 4- IBB ligand in a patient having a cardiovascular disease comprising administering to said patient a 4- IBB antagonist.
2. The method of claim 1, wherein said the 4- IBB antagonist is selected from the group consisting of a soluble 4- IBB, a soluble 4- IBB ligand, an antagonistic antibody that specifically binds 4- IBB and an antagonistic antibody that specifically binds 4- IBB ligand.
3. The method of claim 1, wherein the cardiovascular disease is selected from the group consisting of arrythmia, myocarditis, pericarditis, cardiomyopathy, chronic heart failure, cardiac infarction and cardiotoxicity resulting from treatment with an anthracycline.
4. The method of claim 2, wherein the antagonist is a soluble 4- IBB ligand which further comprises an immunoglobulin Fc domain.
5. The method of claim 2, wherein the 4- IBB antagonist is an antagonistic antibody that specifically binds 4- IBB or 4- IBB ligand.
6. The method of claim 5, wherein the antibody binds specifically to the extracellular domain of 4- IBB ligand.
7. The method of claim 5, wherein the antibody is a humanized antibody.
8. The method of claim 5, wherein the antibody is a human antibody.
9. The method of claim 5, wherein the antibody is a single-chain antibody.
10. The method of claim 1, wherein the mode of administering the 4- IBB antagonist is selected from the group consisting of injection, intravenous administration, oral administration, pulmonary administration, nasal administration, semi-permeable implant and transdermal administration.
11. The method of claim 10, wherein the 4- IBB antagonist is administered in a sustained- release form.
80
12. The method of claim 1, wherein the 4- IBB antagonist is administered in combination with one or more compounds selected from the group consisting of non-steroidal anti- inflammatory drugs; analgesics; systemic steroids; antagonists of inflammatory cytokines; anti-inflammatory cytokines; chemotherapeutic agents; lipid-lowering drugs; blood pressure- regulating drugs; angiotensin-converting enzyme inhibitors and/or peroxisome proliferator- activated receptor ligands.
13. The method of claim 3, wherein the subject suffers from cardiotoxicity resulting from treatment with an anthracycline.
14. The method of 13, wherein the anthracylcine is selected from the group consisting of doxorubicin, daunorubicin, epirubicin, idarubicin and mitroxantrone.
15. The method of claim 13, in which the 4-1BB antagonist is administered prior to, concurrently with or subsequent to treatment with anthracycline.
16. The method of claim 13, wherein the 4- IBB antagonist is administered in an amount sufficient to improve a cardiac condition in said subject, wherein said cardiac condition is selected from the group consisting of arrythmia, myocarditis, pericarditis, myocardial infarction and cardiomyopathy.
17 The method of claim 13, wherein the subject is a cancer patient.
18. The method of claim 13, wherein the 4- IBB antagonist is administered in an amount sufficient to prevent or reduce apoptosis in cardiac tissue of said subject.
19. The method of claim 13, wherein the 4-1BBL antagonist is an antagonistic antibody that specifically binds 4- IBB ligand.
81
PCT/US2003/026354 2002-08-28 2003-08-21 Compositions and methods for treating cardiovascular disease WO2004019866A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
MXPA05002219A MXPA05002219A (en) 2002-08-28 2003-08-21 Compositions and methods for treating cardiovascular disease.
CA2496795A CA2496795C (en) 2002-08-28 2003-08-21 Compositions and methods for treating cardiovascular disease
EP03791726A EP1545578A4 (en) 2002-08-28 2003-08-21 Compositions and methods for treating cardiovascular disease
JP2004532947A JP2006508056A (en) 2002-08-28 2003-08-21 Compositions and methods for treating cardiovascular disease
AU2003259995A AU2003259995B2 (en) 2002-08-28 2003-08-21 Compositions and methods for treating cardiovascular disease

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US40641802P 2002-08-28 2002-08-28
US60/406,418 2002-08-28
US49445703P 2003-08-12 2003-08-12
US60/494,457 2003-08-12

Publications (3)

Publication Number Publication Date
WO2004019866A2 WO2004019866A2 (en) 2004-03-11
WO2004019866A3 WO2004019866A3 (en) 2004-07-08
WO2004019866B1 true WO2004019866B1 (en) 2004-10-14

Family

ID=31981396

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/026354 WO2004019866A2 (en) 2002-08-28 2003-08-21 Compositions and methods for treating cardiovascular disease

Country Status (8)

Country Link
US (3) US20040136992A1 (en)
EP (1) EP1545578A4 (en)
JP (1) JP2006508056A (en)
AU (1) AU2003259995B2 (en)
CA (1) CA2496795C (en)
MX (1) MXPA05002219A (en)
PL (1) PL376536A1 (en)
WO (1) WO2004019866A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8323959B2 (en) 2003-06-18 2012-12-04 Genelux Corporation Microorganisms for therapy

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8246671B2 (en) 1999-08-09 2012-08-21 Cardiokinetix, Inc. Retrievable cardiac devices
US10307147B2 (en) 1999-08-09 2019-06-04 Edwards Lifesciences Corporation System for improving cardiac function by sealing a partitioning membrane within a ventricle
US7674222B2 (en) 1999-08-09 2010-03-09 Cardiokinetix, Inc. Cardiac device and methods of use thereof
US8388672B2 (en) 1999-08-09 2013-03-05 Cardiokinetix, Inc. System for improving cardiac function by sealing a partitioning membrane within a ventricle
US9694121B2 (en) 1999-08-09 2017-07-04 Cardiokinetix, Inc. Systems and methods for improving cardiac function
US8529430B2 (en) 2002-08-01 2013-09-10 Cardiokinetix, Inc. Therapeutic methods and devices following myocardial infarction
US8257428B2 (en) 1999-08-09 2012-09-04 Cardiokinetix, Inc. System for improving cardiac function
US9332993B2 (en) 2004-08-05 2016-05-10 Cardiokinetix, Inc. Devices and methods for delivering an endocardial device
US10064696B2 (en) 2000-08-09 2018-09-04 Edwards Lifesciences Corporation Devices and methods for delivering an endocardial device
US9078660B2 (en) 2000-08-09 2015-07-14 Cardiokinetix, Inc. Devices and methods for delivering an endocardial device
US9332992B2 (en) 2004-08-05 2016-05-10 Cardiokinetix, Inc. Method for making a laminar ventricular partitioning device
US7291331B1 (en) 2002-09-11 2007-11-06 La Jolla Institute For Allergy And Immunology Methods of treating OX40 medicated recall immune responses
WO2004091517A2 (en) * 2003-04-15 2004-10-28 Smithkline Beecham Corporation Conjugates comprising human il-18 and substitution mutants thereof
US7288638B2 (en) 2003-10-10 2007-10-30 Bristol-Myers Squibb Company Fully human antibodies against human 4-1BB
GB0417487D0 (en) 2004-08-05 2004-09-08 Novartis Ag Organic compound
US20070238658A1 (en) * 2005-09-28 2007-10-11 Levin Steven D IL-17A and IL-17F Antagonists and Methods of Using the Same
TWI461436B (en) 2005-11-25 2014-11-21 Kyowa Hakko Kirin Co Ltd Human monoclonal antibody human cd134 (ox40) and methods of making and using same
ZA200804868B (en) 2005-12-16 2009-10-28 Genentech Inc Anti-OX40L antibodies and methods using same
EP1986735A4 (en) 2006-02-06 2011-06-29 Northwind Ventures Systems and methods for volume reduction
CN101668776A (en) * 2007-02-27 2010-03-10 健泰科生物技术公司 Antagonist ox40 antibodies and their use in the treatment of inflammatory and autoimmune diseases
WO2008109379A1 (en) * 2007-03-02 2008-09-12 Mdrna, Inc. Nucleic acid compounds for inhibiting il17a gene expression and uses thereof
PE20091174A1 (en) 2007-12-27 2009-08-03 Chugai Pharmaceutical Co Ltd LIQUID FORMULATION WITH HIGH CONCENTRATION OF ANTIBODY CONTENT
WO2011056578A2 (en) 2009-10-26 2011-05-12 Cardiokinetix, Inc. Ventricular volume reduction
US9284283B2 (en) 2012-02-02 2016-03-15 Ensemble Therapeutics Corporation Macrocyclic compounds for modulating IL-17
CA2897941A1 (en) * 2013-01-17 2014-07-24 Moderna Therapeutics, Inc. Signal-sensor polynucleotides for the alteration of cellular phenotypes
RU2017114607A (en) 2014-09-28 2018-10-29 Кардиокинетикс, Инк. DEVICES FOR THERAPY OF HEART FUNCTIONAL DISORDERS
AU2016285858A1 (en) * 2015-06-30 2017-11-30 Boehringer Ingelheim International Gmbh Multi-specific binding proteins
EP3192805A1 (en) * 2016-01-15 2017-07-19 Humanitas Mirasole S.p.A. Inhibitors of t cell activation or stimulation and uses thereof
DE102018107407A1 (en) 2017-03-28 2018-10-04 Edwards Lifesciences Corporation POSITIONING, INSERTING AND RETRIEVING IMPLANTABLE DEVICES
CN111320691B (en) * 2018-12-17 2022-04-05 程联胜 Anti-human 4-1BB monoclonal antibody and application thereof
CN113234139A (en) * 2020-04-17 2021-08-10 百奥赛图江苏基因生物技术有限公司 TNFSF9 gene humanized non-human animal and construction method and application thereof

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5457A (en) 1848-02-22 Behch-vise
US4737462A (en) 1982-10-19 1988-04-12 Cetus Corporation Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of interferon-β
US4518584A (en) 1983-04-15 1985-05-21 Cetus Corporation Human recombinant interleukin-2 muteins
ATE81722T1 (en) 1984-07-24 1992-11-15 Coselco Mimotopes Pty Ltd PROCEDURE FOR DETERMINING MIMOTOPS.
US4751180A (en) 1985-03-28 1988-06-14 Chiron Corporation Expression using fused genes providing for protein product
US4935233A (en) 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
US5071972A (en) 1986-01-31 1991-12-10 Genetics Institute, Inc. DNA sequences encoding novel thrombolytic proteins
CH671155A5 (en) 1986-08-18 1989-08-15 Clinical Technologies Ass
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5011912A (en) 1986-12-19 1991-04-30 Immunex Corporation Hybridoma and monoclonal antibody for use in an immunoaffinity purification system
EP0315456B1 (en) 1987-11-05 1994-06-01 Hybritech Incorporated Polysaccharide-modified immunoglobulins having reduced immunogenic potential or improved pharmacokinetics
US20060002904A9 (en) * 1988-11-07 2006-01-05 Kwon Byoung S Receptor and related products and methods
US6362325B1 (en) * 1988-11-07 2002-03-26 Advanced Research And Technology Institute, Inc. Murine 4-1BB gene
US6303121B1 (en) * 1992-07-30 2001-10-16 Advanced Research And Technology Method of using human receptor protein 4-1BB
US5116964A (en) 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
ES2246502T3 (en) 1990-08-29 2006-02-16 Genpharm International, Inc. TRANSGENIC NON-HUMAN ANIMALS ABLE TO PRODUCE HETEROLOGICAL ANTIBODIES.
US5716805A (en) 1991-10-25 1998-02-10 Immunex Corporation Methods of preparing soluble, oligomeric proteins
US5262522A (en) 1991-11-22 1993-11-16 Immunex Corporation Receptor for oncostatin M and leukemia inhibitory factor
WO1993024135A1 (en) 1992-05-26 1993-12-09 Immunex Corporation Novel cytokine that binds cd30
US5792451A (en) 1994-03-02 1998-08-11 Emisphere Technologies, Inc. Oral drug delivery compositions and methods
DE69334100T2 (en) 1992-11-13 2007-07-19 Immunex Corp., Seattle ELK LIGAND, A CYTOKIN
US7211259B1 (en) * 1993-05-07 2007-05-01 Immunex Corporation 4-1BB polypeptides and DNA encoding 4-1BB polypeptides
WO1994026290A1 (en) 1993-05-07 1994-11-24 Immunex Corporation Cytokine designated 4-1bb ligand and human receptor that binds thereto
US6274711B1 (en) * 1993-06-14 2001-08-14 Inserm, Institut National De La Sante Et De La Recherche Medicale Purified mammalian CTLA-8 antigens and related reagents
US5457035A (en) 1993-07-23 1995-10-10 Immunex Corporation Cytokine which is a ligand for OX40
US5470952A (en) 1993-10-20 1995-11-28 Regeneron Pharmaceuticals, Inc. CNTF and IL-6 antagonists
US5821332A (en) 1993-11-03 1998-10-13 The Board Of Trustees Of The Leland Stanford Junior University Receptor on the surface of activated CD4+ T-cells: ACT-4
US6242566B1 (en) 1994-02-10 2001-06-05 Board Of Trustees Of The Leland Stanford Junior University Ligand (ACT-4-L) to a receptor on the surface of activated CD4+ T-cells
US6407059B1 (en) 1994-06-08 2002-06-18 Peptor Limited Conformationally constrained backbone cyclized peptide analogs
US6309853B1 (en) 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
US6169073B1 (en) 1995-02-16 2001-01-02 Bayer Corporation Peptides and peptidomimetics with structural similarity to human p53 that activate p53 function
US5877155A (en) 1995-03-17 1999-03-02 The Research Foundation Of State University Of New York Mimotopes and anti-mimotopes of human platelet glycoprotein Ib/IX
WO1996029408A1 (en) 1995-03-23 1996-09-26 Immunex Corporation Il-17 receptor
DK0766745T3 (en) * 1995-04-08 2002-11-25 Lg Chemical Ltd Monoclonal antibody specific for human 4-1BB as well as cell line producing this
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
US6127977A (en) 1996-11-08 2000-10-03 Cohen; Nathan Microstrip patch antenna with fractal structure
US5776731A (en) 1996-02-21 1998-07-07 Immunex Corporation DNA encoding type-I interleukin-I receptor-like protein designated 2F1
DE69731289D1 (en) 1996-03-18 2004-11-25 Univ Texas IMMUNGLOBULIN-LIKE DOMAIN WITH INCREASED HALF-VALUE TIMES
EP1669454A3 (en) 1996-06-27 2009-04-01 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Genomic DNA encoding a polypeptide capable of inducing the production of interferon-gamma
TW515843B (en) 1996-07-25 2003-01-01 Hayashibara Biochem Lab Process for producing an active polypeptide inducing interferon-γ production
EP0959897B1 (en) * 1996-11-27 2009-04-22 Immunex Corporation Method of regulating nitric oxide production
US6087116A (en) 1997-03-12 2000-07-11 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Interleukin-18 (IL-18) receptor polypeptides and their uses
IL121860A0 (en) 1997-08-14 1998-02-22 Yeda Res & Dev Interleukin-18 binding proteins their preparation and use
AU737592B2 (en) 1998-01-23 2001-08-23 Immunex Corporation Il-18 receptors
AU747063B2 (en) * 1998-03-05 2002-05-09 Merckle Gmbh Utilization of CD137 in order to promote the proliferation of peripheral monocytes
AU6425699A (en) 1998-10-16 2000-05-08 Cornell Research Foundation Inc. Methods of inhibiting platelet activation and recruitment
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
KR20000034847A (en) * 1998-11-17 2000-06-26 성재갑 Humanized Antibody Specific for Human 4-1BB Molecule and Pharmaceutical Composition Comprising Same
MXPA03003407A (en) * 2000-10-18 2004-05-04 Immunex Corp Methods for treating rheumatoid arthritis using il-17 antagonists.
US20040028687A1 (en) * 2002-01-15 2004-02-12 Waelti Ernst Rudolf Methods and compositions for the targeted delivery of therapeutic substances to specific cells and tissues
WO2004055513A2 (en) 2002-12-16 2004-07-01 Herbert Schwarz Use of cd137 antagonists for the treatment of tumors

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8323959B2 (en) 2003-06-18 2012-12-04 Genelux Corporation Microorganisms for therapy

Also Published As

Publication number Publication date
CA2496795A1 (en) 2004-03-11
CA2496795C (en) 2014-06-03
EP1545578A2 (en) 2005-06-29
WO2004019866A2 (en) 2004-03-11
US20120263729A1 (en) 2012-10-18
US8529894B2 (en) 2013-09-10
AU2003259995A1 (en) 2004-03-19
AU2003259995B2 (en) 2009-07-02
JP2006508056A (en) 2006-03-09
MXPA05002219A (en) 2005-07-05
EP1545578A4 (en) 2010-07-07
US20130323258A1 (en) 2013-12-05
US20040136992A1 (en) 2004-07-15
WO2004019866A3 (en) 2004-07-08
PL376536A1 (en) 2006-01-09

Similar Documents

Publication Publication Date Title
WO2004019866B1 (en) Compositions and methods for treating cardiovascular disease
JP2006508056A5 (en)
Gillis et al. Octreotide long-acting release (LAR) A review of its pharmacological properties and therapeutic use in the management of acromegaly
Advani et al. A phase I trial of doxorubicin, paclitaxel, and valspodar (PSC 833), a modulator of multidrug resistance
Sitbon et al. EPITOME-2: an open-label study assessing the transition to a new formulation of intravenous epoprostenol in patients with pulmonary arterial hypertension
Kolka et al. The barrier within: endothelial transport of hormones
KR20110050583A (en) Induction of tumor hypoxia for cancer therapy
Zonnenberg et al. Phase I dose-escalation study of the safety and pharmacokinetics of atrasentan: an endothelin receptor antagonist for refractory prostate cancer
KR20160078987A (en) Cancer treatment with combination of plinabulin and taxane
US20230235083A1 (en) Combination therapy using a liv1-adc and a chemotherapeutic
Takano et al. Metronomic treatment of malignant glioma xenografts with irinotecan (CPT-11) inhibits angiogenesis and tumor growth
Grünig et al. Safety, tolerability and clinical effects of a rapid dose titration of subcutaneous treprostinil therapy in pulmonary arterial hypertension: a prospective multi-centre trial
US10376597B2 (en) Targeting tumor cells with chemotherapeutic agents conjugated to matriptase antibodies
US20070105817A1 (en) Use of cicletanine and other furopyridines for treatment of systolic-predominant hypertension, isolated systolic hypertension, elevated pulse pressure, and general hypertension
Schaffler et al. Comparison of the analgesic effects of a fixed-dose combination of orphenadrine and diclofenac (Neodolpasse®) with its single active ingredients diclofenac and orphenadrine: A Placebo-controlled study using laser-induced somatosensory-evoked potentials from capsaicin-induced hyperalgesic human skin
SK287762B6 (en) Use of aplidine in preparation of pharmaceutical composition for treating cancer
US20050281867A1 (en) Nitric oxide inducing agents
Allen Dexamethasone: An all purpose agent?
Fenton et al. Telmisartan/hydrochlorothiazide: in the treatment of essential hypertension
DE102007041832A1 (en) Medicines and methods for the treatment of prostate cancer
KR102471267B1 (en) Methods of targeting tumor cells using chemotherapeutic agents conjugated to anti-Matriptase antibodies by in vivo cleavable linking moieties
Weathers et al. Results of a phase I trial to assess the safety of macitentan in combination with temozolomide for the treatment of recurrent glioblastoma
US20050119263A1 (en) Treatment of breast cancer
Blowers et al. Adverse events in bevacizumab and chemotherapy: patient management
Bruderer et al. Influence of severe renal impairment on the pharmacokinetics of clazosentan

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
B Later publication of amended claims

Effective date: 20040513

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
ENP Entry into the national phase

Ref document number: 2496795

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 376536

Country of ref document: PL

Ref document number: PA/a/2005/002219

Country of ref document: MX

Ref document number: 2004532947

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2003259995

Country of ref document: AU

REEP Request for entry into the european phase

Ref document number: 2003791726

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2003791726

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2003791726

Country of ref document: EP